NICE Back’s Routine Use of Incyte’s Iclusig

February 22, 2017

The UK’s National Institute for Health and Care Excellence has backed the routine use of Incyte's Iclusig by the National Health Service to treat some patients with chronic myeloid leukemia (CML) and acute lymphoblastic leukemia.

NICE recommends the use of Iclusig (ponatinib) in adults with chronic phase CML who have the rare T315I mutation and in those with accelerated or blast phase CML whose disease is resistant to dasatinib or nilotinib.

Iclusig is currently available to patients via the Cancer Drugs Fund.

View today's stories